Reproductive Health Innovation Summit

Reproductive Health Innovation Summit – The 10 winners chosen by our selection committee will pitch their company in both Boston and the real world in September at a fast pace.

We want to hear 10 unique ideas about the future of women’s health and what your companies’ role is in this journey. Our platform aims to give voice to innovation that “moves the needle” on women’s health and put it in front of decision makers who can accelerate that vision.

Reproductive Health Innovation Summit

Editing tip: The more detailed your application form is, the more information the selection committee can use to make a decision. All applications are confidential and information will not be shared outside of the committee. However, if you don’t want to fill out the question, feel free to leave it blank.

Air Force Medical Service Hosts Innovation Summit, Prepares For Future Challenges > Air Force Medical Service > Display

Calling all women’s health designers and startups! Organon seeks smart and innovative solutions to address unmet women’s health needs. A global Fortune 500 healthcare company wants to learn about game-changing ideas in healthcare, including pharmaceuticals, medical devices, diagnostics and other technologies.

Organon is a new company that started with the vision of being a leading women’s health company. We want to partner with innovators to address conditions that are specific to women (eg conception, contraception, childbirth, menopause) or that primarily affect women (eg migraines, osteoporosis).

If you are selected for the Organon Innovation Conference, you will have the opportunity to present and discuss your innovation in a closed session with Organon R&D scientists and clinical leaders and business development experts. You are invited to join the reception to meet and network with others who are committed to providing solutions for women’s health. Register your interest in WHIS Asia 2024, stay updated and be the first to see our ambitions!

WHIS Asia 2023 post-event report coming soon! Find out who was in the room, our Showcase winner, our FemTech award winners and more.

Are Investors Missing Out On The Vast Potential Of Women’s Health?

Nowhere do we see more buzz in femtech and women’s lifestyle innovation than in Asia, so we’re excited to bring you our series!

The Asia Women’s Health Innovation Summit focuses on key challenges facing all aspects of women’s health, with programs covering menstrual care, reproductive health, sexual health and menopause care, among others.

Our conference brought together key leaders who are creating the environment for women’s health in Asia. Including startups and femtechs, investors, charities and large corporations, private and non-profit organizations, government policy makers, large pharmaceutical and medical device companies, insurance companies, organizations and public platforms.

It was amazing to see our room of industry leaders grow the unmet needs of women in Asia by sharing information, making connections and driving innovation!

The Power Of Research For Advancing Reproductive Health

Free to apply, Asia’s first women’s health innovation conference highlights the best of FemTech and women’s health innovations from the region.

Eight startups will be selected by our prestigious selection committee to pitch in front of an audience of over 150 leading strategic partners and investors.

Through a series of fast-paced presentations, these pioneers will present their vision for the future of improving women’s health and how their product, technology or service is paving the way to improve the lives of women in Asia.

This year, for the first time, WHIS and FAA will host an intimate awards evening celebrating inspiring leaders, outstanding innovations and impressive achievements in the femtech and broader healthcare industry. the beauty of women. It was a festive and fun evening at a special place in Singapore.

Ethealthworld Fertility Conclave 2023 Convening Fertility Experts To Deliberate On Challenges, Advancements And Future, Health News, Et Healthworld

Organon (NYSE: OGN ) is a global healthcare company created by Merck, known as MSD outside of the United States and Canada, to focus on improving women’s health across the lifespan. they see Here for his health, the company has a collection of more than 60 medicines and products in various fields of treatment. Led by the Center for Reproductive Health, along with a growing biosimilars business and a strong drug business, Organon’s products generate strong cash flow that will support investments, future growth opportunities in Women’s Lives, including business development. In addition, Organon is seeking collaboration opportunities with biopharmaceutical innovators who want to market their products by raising their profile and presence in fast-growing international markets. Organon has a global footprint with significant scale and geographic reach, world-class business capabilities and approximately 9,000 employees headquartered in Jersey City, New Jersey.

As an independent biopharmaceutical company, Ferring is focused on developing life-changing solutions that help people live better lives. Based on a 70-year commitment to science and research, we are committed to developing treatments that help people start families, stay healthy and fight disease.

Our goal is to be a leading global healthcare company, the most trusted in reproductive medicine and maternal health, and a leader in the specialty areas of gastroenterology and bone marrow. With this ambition in mind, we’re committed to following science, conducting comprehensive research and going where others can’t – which means people always come first.

Since our US operations began in 1980, Ferring has continued to maintain record growth, introduce new products and expand operations. Today, through our new research and discovery strategies, we are working to achieve today’s “firsts”: unlocking the power of the human microbiome, discovering new, more accessible ways for people to create and build families, and tackling many other disruptive challenges. Diseases and conditions of our time.

Swhr Ceo Reflects On Reproductive Health Innovation Summit

There was a time when economic growth, stability and inclusiveness were seen as a trade-off, but today’s leaders must achieve all three. This new growth model will be more sustainable, stimulating innovation and reducing environmental impact. It will also be more inclusive and create access to opportunities around the world.

This is no easy task, but McKinsey & Company’s passion is to help organizations and their leaders make it happen. They combine bold strategies and transformative technologies to help organizations achieve sustainable innovation, sustainable productivity gains, and build a workforce that thrives for this generation and the next.

GSK is focused on improving patients’ lives with life-changing medicines. Our oncology pipeline focuses on immuno-oncology, cell therapy, tumor cell-targeted therapy and synthetic diseases. Our goal is to achieve a steady stream of new treatments based on a variety of investigational drugs.

Gynecological cancer is the most common in women. An estimated 1.4 million people will be diagnosed with cervical, endometrial, ovarian, vaginal, or vulvar cancer in 2020; However, awareness about this cancer and its symptoms remains low. At GSK, we are committed to supporting ongoing innovation in gynecologic cancer by keeping the patient’s voice at the center of our mission and creating new programs to meet their needs. For more information about our work in oncology, visit:

Dr. Lisa Campo Engelstein Panelist At The Reproductive Health Innovation Summit

We seek to redefine care for women and men through targeted science, drug empowerment, and transformative advocacy.

Our goals are defined and motivated by the opportunity to improve the lives of millions of men and women, many of whom have been affected by illness during their working years. Despite the high burden of common diseases such as uterine fibroids, endometriosis, and prostate cancer, many women and men lack the options they need and need.

Bayer is a recognized leader in women’s health with a long-term commitment to providing science for better lives by developing a range of innovative treatments. Bayer offers a wide range of short-term and long-term birth control methods, as well as menopause and gynecological disease management treatments. Bayer is also looking for new opportunities to address the unmet medical needs of women around the world. Today, Bayer’s research and development efforts are focused on finding new treatments for menopause and gynecological diseases, and include many compounds at various stages of early development and medicine. Together, these projects reflect the company’s approach to research, which prioritizes targets and pathways that have the potential to transform the treatment of women’s diseases. In addition, Bayer plans to provide 100 million women in low- and middle-income countries with access to family planning by 2030 by supporting mass support programs and ensuring the supply of modern, affordable contraceptives. It is part of comprehensive sustainability initiatives and commitments from 2020 onwards and in line with the UN Sustainable Development Goals.

Johnson & Johnson Innovation LLC is focused on accelerating all stages of innovation worldwide and creating partnerships between entrepreneurs and Johnson & Johnson’s global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with one-stop access to science and technology experts who can collaborate with Johnson & Johnson companies, pharmaceutical, medical and consumer companies. Within the Johnson & Johnson Innovation business unit, we connect with innovators through our regional centers; Johnson & Johnson Innovation – JLABS; Johnson & Johnson Innovation – JJDC, Inc.; and our business development teams to create tailored deals and innovative partnerships that accelerate the development of new ways to address unmet patient needs. JLABS provides the labs, expertise, education, tools and equipment life science companies need to thrive, all with no strings attached. At the Texas Medical Center, the Johnson & Johnson Device Innovation Center (CDI @ TMC) was established to accelerate development.

Sexual And Reproductive Justice To Deliver The Nairobi Commitments

Leave a Comment